RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
批准号:
3874539
负责人:
J E JANIK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
biological response modifiers cis platinum compound clinical trials colony stimulating factor combination cancer therapy dosage drug adverse effect granulocytopenia human subject human therapy evaluation immunomodulators immunosuppression neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy ovary neoplasms thrombocytopenia
中文摘要
本试验旨在检测重组粒细胞
巨噬细胞集落刺激因子(rGM-CSF)保护患者
难治性卵巢癌的骨髓抑制作用
大剂量卡铂 之前的一项研究显示,
在晚期卵巢癌患者中,
carcinoma. 治疗与严重和长期的
骨髓抑制 在这项试验中,卡铂每35
天的剂量为800毫克/平方米。 以不同剂量给予rGM-CSF
从卡铂给药后三天开始。 本研究
正在与国家癌症研究所医学分支联合进行
院 8例患者发生了显著的骨髓抑制
在高剂量卡铂后,除一名患者外,所有患者均需要剂量
由于这种骨髓抑制,化疗减少。 所有
患者出现严重血小板减少症,需要血小板
输血 所有患者在治疗期间都需要住院治疗。
治疗过程。 在接受最高剂量治疗的8名患者中,
GM-CSF水平不需要因粒细胞减少症住院,
发烧 GM-CSF是否能缩短粒细胞减少症的持续时间,
从这项研究中确定。 血小板减少症仍为重度,
延长,似乎没有受到GM-CSF的影响。 八个中的六个
在生物反应调节剂项目中接受治疗的患者是可评价的
来回应。 三个答复,两个部分答复和一个完全答复,
见过
英文摘要
This trial was designed to test the ability of recombinant granulocyte
macrophage-colony stimulating factor (rGM-CSF) to protect patients with
refractory ovarian carcinoma from the bone marrow suppressive effects of
high-dose carboplatinum. A previous study with high-dose carboplatinum
demonstrated a response rate of 27% in patients with advanced ovarian
carcinoma. Therapy was associated with severe and prolonged
myelosuppression. In this trial, carboplatinum was administered every 35
days at a dose of 800 mg/m sq. rGM-CSF was given at various doses
beginning three days after administration of carboplatinum. This study is
being conducted jointly with the Medicine Branch of the National Cancer
Institute. Eight patients experienced significant myelosuppression
following high-dose carboplatinum and all but one patient required dose
reductions in chemotherapy due to this myelosuppression. All of the
patients experienced significant thrombocytopenia and required platelet
transfusions. All of the patients required hospitalization during the
course of therapy. Two of the eight patients treated at the highest dose
level of GM-CSF did not require hospitalization for granulocytopenia and
fever. Whether GM-CSF shortens the duration of granulocytopenia cannot be
determined from this study. Thrombocytopenia has remained severe and
prolonged and appears not to have ben affected by GM-CSF. Six of the eight
patients treated at the Biological Response Modifiers Program are evaluable
for response. Three responses, two partial and one complete response were
seen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:2464506
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
-
批准号:2464513
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I TRIAL OF TNF AND GM-CSF
-
批准号:3752523
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
-
批准号:3752507
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A (R022-8181/002) IN HAIRY CELL LEUKEMIA
-
批准号:3752481
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3838223
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
-
批准号:3853339
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
-
批准号:3838227
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
-
批准号:3838238
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
-
批准号:3752508
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:6163345
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
-
批准号:3838239
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3853335
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
-
批准号:3853315
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:6163429
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE A IFN IN HAIRY CELL LEUKEMIA
-
批准号:3752475
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH RIFN-GAMMA
-
批准号:3752495
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3752497
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3874559
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE INTERFERON ALPHA IN HCL
-
批准号:2464504
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位: